PathScan® Bcr/Abl Activity Assay:

Phospho-c-Abl, Phospho-Stat5 and Phospho-CrkL Multiplex Western Detection Cocktail



rev. 01/29/16



Orders 877-616-CELL (2355)

orders@cellsignal.com

Support 877-678-TECH (8324)

info@cellsignal.com

Web www.cellsignal.com

For Research Use Only. Not For Use In Diagnostic Procedures.


W H Rabbit** Endogenous	Applications	Species Cross-Reactivity*	Source	
	==	Н	Rabbit**	

Antibody Cocktail Components and Molecular Weights				
No.	Antibody	Molecular Weight		
2868	Phospho-c-Abl (Tyr245) (73E5) Rabbit mAb	135 kDa (c-Abl); 210 kDa (Bcr-Abl)		
4322	Phospho-Stat5 (Tyr694) (D47E7) XP® Rabbit mAb	90 kDa		
3181	Phospho-CrkL (Tyr207) Antibody	39 kDa		
5589	Rab11 (D4F5) XP® Rabbit mAb	25 kDa		

Description: The PathScan® Multiplex Western Detection Cocktail offers a unique method to assay the inhibition of multiple proteins on one membrane without stripping and reprobing. This method saves the user valuable time while increasing accuracy and minimizing reagent waste. The Bcr/Abl Activity Assay allows the user to simultaneously detect the inhibition of phosphorylation of c-Abl, Stat5 and CrkL proteins in response to STI-571. The cocktail also includes Rab11 antibody to control protein loading.

Background: STI-571 (also known as Imatinib mesylate) is a tyrosine kinase (TK) inhibitor that is a relatively specific ATP-binding site antagonist of Bcr-Abl, PDGF receptor and c-Kit TKs (1-3). Results are encouraging in CML clinical trials, and STI-571 has become a paradigm for targeted cancer therapeutics (4-6). Signal transduction through phospho-tyrosine pathways has been studied extensively, and tyrosine phosphorylation has been linked to multiple cell growth and differentiation pathways (7-9). Because the observed leukemic state of CML is dependent on the intact Bcr-Abl tyrosine kinase activity, extensive work has been done to identify substrates of Bcr-Abl and thus possible mechanisms leading to a myeloid expansion. Many groups have characterized prominent tyrosine-phosphorylated protein substrates in both CML blasts and Bcr-Abl-expressing cell lines, including SHIP, c-cbl, Dok, SHC and CrkL (10-15). In addition, key signal transduction pathways involving PI3 kinase, Ras, Myc and Stat5 are also activated in a Bcr-Abl kinase-dependent manner (16).

Specificity/Sensitivity: Each phospho-antibody in this cocktail recognizes endogenous levels of only the phosphorylated form of its specific target. The Rab11 Antibody detects endogenous levels of its target protein independent of phosphorylation and is provided to control for protein loading.



Western blot analysis of extracts from K562 cells untreated or STI-571 treated, using PathScan Bcr/Abl Activity Assay cocktail.

Source/Purification: Antibodies are produced by immunizing animals with synthetic peptides. Polyclonal antibodies are purfied by protein A and peptide affinity chromatography.

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA and 50% glycerol. Store at -20° C. *Do not aliquot the antibody.*

- *Species cross-reactivity is determined by western blot, using the individual antibody cocktail components.
- **Anti-rabbit secondary antibodies must be used to detect this antibody.

Recommended Antibody Dilutions:

Western blotting 1:250

Background References:

- (1) Buchdunger, E. et al. (1996) Cancer Res. 56, 100-104.
- (2) Heinrich, M. et al. (2000) Blood 96, 925-932.
- (3) Druker, B.J. et al. (1996) Nat. Med. 2, 561-566.
- (4) Mauro, M.J. and Druker, B.J. (2001) Curr. Oncol. Rep. 3, 223–227.
- (5) Druker, B.J. et al. (2001) N. Engl. J. Med. 344, 1031-1037.
- (6) Druker, B.J. et al. (2001) N. Engl. J. Med. 344, 1038-1042.
- (7) Blume-Jensen, P. and Hunter, T. (2001) *Nature* 411, 355–365.
- (8) Ullrich, A. and Schlessinger, J. (1990) Cell 61, 203-212.
- (9) Cantley, L.C. et al. (1991) Cell 64, 281-302.
- (10) Hoeve, J. et al. (1994) Blood 84, 1731-1736.
- (11) Matsuguchi, T. et al. (1994) J. Biol. Chem. 269, 5016-5021.
- (12) Carpino, N. et al. (1997) Cell 88, 197-204.
- (13) Sattler, M. et al. (1997) Oncogene 15, 2379-2384.
- (14) Di Cristofano, A. et al. (1998) *J. Biol. Chem.* 273, 4827–4830.
- (15) Wisniewski, D. et al. (1999) Blood 93, 2707-2720.
- (16) Kabarowski, J.H. and Witte, O.N. (2000) *Stem Cells* 18, 399–408.

IMPORTANT: For western blots, incubate membrane with diluted antibody in 5% w/v BSA, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight.

U.S. Patent No. 5,675,063



Western Immunoblotting Protocol (Primary Antibody Incubation in BSA)

For Western blots, incubate membrane with diluted antibody in 5% w/v BSA, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight.

A Solutions and Reagents

NOTE: Prepare solutions with Milli-Q or equivalently purified water.

- 1. 1X Phosphate Buffered Saline (PBS)
- 1X SDS Sample Buffer: 62.5 mM Tris-HCI (pH 6.8 at 25°C), 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v bromophenol blue or phenol red
- 3. Transfer Buffer: 25 mM Tris base, 0.2 M glycine, 20% methanol (pH 8.5)
- 10X Tris Buffered Saline (TBS): To prepare 1 liter of 10X TBS: 24.2 g Tris base, 80 g NaCl; adjust pH to 7.6 with HCl (use at 1X).
- 5. Nonfat Dry Milk (weight to volume [w/v])
- Blocking Buffer: 1X TBS, 0.1% Tween-20 with 5% w/v nonfat dry milk; for 150 ml, add 15 ml 10X TBS to 135 ml water, mix. Add 7.5 g nonfat dry milk and mix well. While stirring, add 0.15 ml Tween-20 (100%).
- 7. Wash Buffer: 1X TBS, 0.1% Tween-20 (TBS/T)
- 8. Bovine Serum Albumin (BSA)
- Primary Antibody Dilution Buffer: 1X TBS, 0.1% Tween-20 with 5% BSA; for 20 ml, add 2 ml 10X TBS to 18 ml water, mix. Add 1.0 g BSA and mix well. While stirring, add 20 µl Tween-20 (100%).
- 10. Phototope®-HRP Western Blot Detection System #7071: Includes biotinylated protein ladder, secondary anti-rabbit (#7074) antibody conjugated to horseradish peroxidase (HRP), anti-biotin antibody conjugated to HRP, LumiGLO® chemiluminescent reagent and peroxide.
- 11. Prestained Protein Marker, Broad Range (Premixed Format) #7720
- **12.** Biotinylated Protein Ladder Detection Pack #7727
- Blotting Membrane: This protocol has been optimized for nitrocellulose membranes, which CST recommends. PVDF membranes may also be used.

B Protein Blotting

A general protocol for sample preparation is described below.

- 1. Treat cells by adding fresh media containing regulator for desired time.
- 2. Aspirate media from cultures; wash cells with 1X PBS; aspirate.
- 3. Lyse cells by adding 1X SDS sample buffer (100 µl per well of 6-well plate or 500 µl per plate of 10 cm diameter plate). Immediately scrape the cells off the plate and transfer the extract to a microcentrifuge tube. Keep on ice.
- 4. Sonicate for 10-15 seconds to shear DNA and reduce sample viscosity.
- **5.** Heat a 20 μ l sample to 95–100°C for 5 minutes; cool on ice.
- 6. Microcentrifuge for 5 minutes.
- 7. Load 20 µl onto SDS-PAGE gel (10 cm x 10 cm).

NOTE: CST recommends loading prestained molecular weight markers (#7720, 10 μ I/lane) to verify electrotransfer and biotinylated protein ladder (#7727, 10 μ I/lane) to determine molecular weights.

8. Electrotransfer to nitrocellulose or PVDF membrane.

C Membrane Blocking and Antibody Incubations

NOTE: Volumes are for 10 cm x 10 cm (100 cm²) of membrane; for different sized membranes, adjust volumes accordingly.

- (Optional) After transfer, wash nitrocellulose membrane with 25 ml TBS for 5 minutes at room temperature.
- 2. Incubate membrane in 25 ml of blocking buffer for 1 hour at room temperature.
- 3. Wash three times for 5 minutes each with 15 ml of TBS/T.
- Incubate membrane and primary antibody (at the appropriate dilution) in 10 ml primary antibody dilution buffer with gentle agitation <u>overnight</u> at 4°C.
- 5. Wash three times for 5 minutes each with 15 ml of TBS/T.
- 6. Incubate membrane with HRP-conjugated secondary antibody (1:2000) and HRP-conjugated anti-biotin antibody (1:1000) to detect biotinylated protein markers in 10 ml of blocking buffer with gentle agitation for 1 hour at room temperature.
- 7. Wash three times for 5 minutes each with 15 ml of TBS/T.

D Detection of Proteins

 Incubate membrane with 10 ml LumiGL0® (0.5 ml 20X LumiGL0®, 0.5 ml 20X Peroxide and 9.0 ml Milli-Q water) with gentle agitation for 1 minute at room temperature.

NOTE: LumiGLO® substrate can be further diluted if signal response is too fast.

Drain membrane of excess developing solution (do not let dry), wrap in plastic wrap and expose to x-ray film. An initial 10-second exposure should indicate the proper exposure time.

NOTE: Due to the kinetics of the detection reaction, signal is most intense immediately following LumiGLO® incubation and declines over the following 2 hours.



Material Safety Data Sheet (MSDS) for Antibodies



rev. 08/09/07

I. Identification:

Product name: Antibodies

Product Catalog Number: Includes antibodies within the following range of catalog num-

bers: 2000-5999, 7000-7999 and 9000-9999.

CAS number: None

Manufacturer Supplier: Cell Signaling Technology

3 Trask Lane

Danvers, MA 01923 USA 1-978-867-2300 TEL 1-978-867-2400 FAX

1-978-578-6737 Emergency Phone

II. Composition/Information on Ingredients:

This product is composed of antibodies in aqueous buffer solution. According to 29 CFR 1910.1200(d), hazardous ingredients at less than <1% and carcinogens at less than < 0.1% are considered non-hazardous. Any hazardous or carcinogenic ingredients exceeding these criteria are listed below.

This product may contain the following hazardous ingredients.

Ingredient	CAS#	Percent
Glycerol	56-81-5	50%

III. Hazard Identification:

Emergency Overview of Hazardous ingredient: Glycerol (CAS# 56-81-5)

Caution: Avoid contact and inhalation.

Target Organ: Kidneys.

NFPA Rating:

Health Rating: 1
Flammability Rating: 0
Reactivity Rating: 0

IV. First Aid Measures:

Inhalation: If inhaled, remove to fresh air. If breathing is difficult, get medical attention. **Ingestion:** If swallowed and person is conscious, rinse out mouth with water. Get medical attention.

Skin Exposure: In case of contact, wash skin with soap and water.

Eye Exposure: In case of contact with eyes, immediately flush eyes water for at least 15 minutes. Get medical attention.

milatos. doi modical attention.

V. Fire Fighting Measures:

Flash Point: Data not available.

Autoignition Temperature: Data not available.

Fire Extinguishing Media: Water spray, dry chemical, foam, or carbon dioxide. Firefighting: Wear protective clothing and self-contained breathing apparatus to prevent

contact with skin and eyes.

VI. Accidental Release Measures:

Absorb liquid with an absorbent material. Transfer contaminated absorbent to a chemical waste container for disposal.

VII. Handling And Storage:

Avoid inhalation and contact with eyes and skin. Avoid prolonged or repeated exposure. Store at –20°C in tightly closed container.

VIII. Exposure Controls/Personal

Engineering Controls: Maintain adequate ventilation, eye wash and quick-drench facilities in work area

Personal Protective Equipment: Lab coat, chemical resistant gloves and chemical safety

Occupational Exposure Limits: Data not available.

IX. Exposure Controls/Personal Protection:

 Physical State:
 Colorless liquid.

 Odor:
 Odorless.

 Boiling Point:
 Data not available.

 Melting Point:
 Data not available.

 Volatile Organic Compound:
 Data not available.

 Solubility in water:
 Readily miscible in water.

X. Stability and Reactivity:

Stability: Stable.

Hazardous Decomposition: May form carbon dioxide and carbon monoxide.

Conditions to avoid: Strong oxidizing agents

XI. Toxicological Information:

May cause skin irritation.

May be toxic if absorbed through skin or ingested.

May cause eye irritation.

Target Organs: Kidneys

Prolonged exposure may cause nausea, headache, and vomiting.

XII. Ecological Information:

Data not available.

XIII. Disposal Considerations:

Dispose of in accordance with federal, state and local environmental regulations.

XIV. Transport Information:

D.O.T.: This substance is considered non-hazardous for transport. **IATA:** This substance is considered non-hazardous for air transport.

XV. Regulatory Information:

EU Regulation/Classification/Labeling Information: Not available for this product.

Chemical Inventory Status: SARA Listed Component: None. TSCA Listed Component: None. Canada (WHMIS): DSL No, NDSL No.

XVI. Other Information:

This compound is sold only for research use by personnel familiar with chemicals and who are well trained in good laboratory habits, such as avoiding spills, keeping hands clean at all times and not rubbing eyes with hands while working in the laboratory.

This solution is sold only in microliter quantities for use in life sciences research. No other use is intended, and any other use may involve substantive hazards.

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide for experienced personnel. Cell Signaling Technology, Inc., shall not be held liable for any damage resulting from the handling of or from contact with the above product. The burden of safe use of this material rests entirely with the user.